Gebro Pharma launches Ialuril Prefill, a new Ialuril presentation in the form of prefilled syringes

Gebro Pharma continues to innovate to improve its patients’ quality of life. The pharmaceutical company has launched Ialuril® Prefill, a new presentation of Ialuril in comfortable prefilled syringes for easier and better handling.
Ialuril® Prefill, administered through intravesical route, is a balanced combination of hyaluronate acid, chondroitin sulfate and calcium chloride as excipient, to improve the product’s adhesion to the urothelial layer. These components help restore the protective function of the bladder’s wall.
Specifically, the drug is indicated for the treatment of chronic inflammatory diseases of the bladder caused by damage to the urothelium’s protective layer, such as Painful Bladder Syndrome (PBS) or Interstitial Cystitis (IC), radiation cystitis and chemical cystitis, and recurring and/or chronic bacterial cystitis.

Advantages of the new presentation
This new Ialuril presentation in prefilled syringes offers great advantages in the product’s handling, providing a safer administration since it reduces the product’s risk of contamination when being handled by health professionals.